Rebamipide (Mucosta®), a clinically approved drug, alleviates neuroinflammation and dopaminergic neurodegeneration in a Parkinson’s disease model
Considering its established clinical use, this study supports repurposing rebamipide for treating PD and other NLRP3 inflammasome-driven neuroinflammatory diseases.
Authors
- Gunhyuk Park (ORCID: https://orcid.org/0000-0001-8911-831X)
- Hwi‐yeol Yun (ORCID: https://orcid.org/0000-0001-8793-2449)
- Wonhwa Lee
- Seung Hoon Lee (ORCID: https://orcid.org/0000-0002-0417-2120)
- Jin‐Young Park (ORCID: https://orcid.org/0000-0003-4042-9779)
- Hye‐Sun Lim (ORCID: https://orcid.org/0000-0001-5416-8827)
- Eunjeong Kim
Institutions
- Chungnam National University (KR)
- Kyungpook National University (KR)
- Korea Institute of Oriental Medicine (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Journal of Neuroinflammation
- Published
- 2025-05-17
- DOI
- https://doi.org/10.1186/s12974-025-03461-z
- Citations
- 4
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.56
Funders
- National Research Foundation
- Sungkyunkwan University
- Korea Institute for Advancement of Technology
- Korea Institute of Oriental Medicine
- National Research Foundation of Korea